They are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”) in oncology and inflammation. Their lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously), and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging their TME Normalization Technology, delivered deep into the tumor micro-environment (“TME”). Their proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Their TME Normalization Technology allows their drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. As of the date of this prospectus, they have not generated any revenues. Since inception, they have devoted substantially all of their resources to developing product and technology rights, conducting research and development, organizing and staffing their Company, business planning and raising capital.